Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECT: Bedaquiline SCR for MDR-TB
NCT05306223Phase 4Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- May 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bedaquiline in Tuberculosis (TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Percentage of Participants with a Favorable Treatment Outcome at the End of Treatment at 40 weeks. Status: unknown.
02
Drugs
bedaquiline
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05306223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306223.